Chronic inflammation (CI) is a risk factor for pancreatic cancer (PC) including the most common type, ductal adenocarcinoma (PDAC), but its role and the mechanisms involved are unclear. To investigate the role of CI in PC, we generated genetic mouse models with pancreatic specific CI in the presence or absence of TP53. Mice were engineered to express either cyclooxygenase-2 (COX-2) or IkB kinase-2 (IKK2), and TP53<sup>+/+</sup> or TP53<sup>fl/fl</sup> specifically in adult pancreatic acinar cells by using a full-length pancreatic elastase promoter-driven Cre. Animals were followed for >80 weeks and pancreatic lesions were evaluated histologically and immunohistochemically. The presence of K-ras mutations was assessed by direct sequencing, locked nucleic acid (LNA)-based PCR, and immunohistochemistry. We observed that sustained COX-2/IKK2 expression caused histological abnormalities of pancreas, including increased immune cell infiltration, proliferation rate and DNA damage. A minority of animals with CI developed pre-neoplastic lesions, but cancer was not observed in any TP53<sup>+/+</sup> animals within 84 weeks. In contrast, all animals with CI-lacking TP53 developed various subtypes of PC, including acinar cell carcinoma, ductal adenocarcinoma, sarcomatoid carcinoma and neuroendocrine tumors, and all died within 65 weeks. No evidence of K-ras mutations was observed. Variations in the activity of the Hippo, pERK and c-Myc pathways were found in the diverse cancer subtypes. In summary, chronic inflammation is extremely inefficient at inducing PC in the presence of TP53. However, in the absence of TP53, CI leads to the development of several rare K-ras-independent forms of PC, with infrequent PDAC. This may help explain the rarity of PDAC in persons with chronic inflammatory conditions.
RESULTS

Targeted expression in pancreas of COX-2 and/or IKK2 leads to chronic inflammation but does not readily induce tumorigenesis in the presence of wild-type TP53.

Analysis of pancreatic histology revealed slow progressive chronic inflammation in mice expressing COX-2 (Figure 1A). In the majority of COX-2 expressing mice, the pancreata did not show significant pathological changes at 20 weeks of age, but by weeks 40 and 80, prominent acinar atrophy, vacuolization and moderate levels of acinar to ductal metaplasia (ADM) were evident. At later times, ductal proliferation and ectasia were the most prominent features. Low frequencies of early pancreatic intraepithelial neoplasia (PanIN) lesions (PanIN1 in 35% (7/20); PanIN2 in 5% (1/20)) were observed. (Figure 1A). COX-2 expression caused increased expression of proinflammatory and profibrogenic cytokines (Supplementary Figure 1D). The presence of CI was confirmed by increased immune cell infiltrate including leukocytes and pancreatic stellate cells, with macrophages being the most common. A slow accumulation of collagen deposition was also observed (Figure 1A; Supplementary Figures 2A and B). The progression of changes was associated with an increase in the proliferation rate assessed by Ki-67 staining, with the highest degree of proliferation within ducts (Supplementary Figures 2C and D; Figure 1C). DNA damage was also evident in mice expressing COX-2, as indicated by increased cells with nuclei positive for γH2AX foci (Figure 1C; Supplementary Figure 2E).

The histologic changes in the pancreata of IKK2 expressing mice were generally similar to those of COX-2 expressing mice. Both IKK2 and COX-2 expression caused progressive loss of acinar cells (Figures 1A and B). IKK2 expression induced the infiltration of leukocytes, indicating ongoing inflammation, and increased proliferation rate and DNA damage (Figures 1B and C; Supplementary Figures 2A and C-E). However, unlike COX-2 mice, IKK2 bearing mice showed no evidence of ADM and the most prominent histologic change was fatty replacement of the pancreas. In addition, IKK2 bearing mice showed no increase in pancreatic fibrosis (Figure 1B). Despite prominent chronic inflammatory changes, neither the expression of COX-2 nor IKK2 nor the expression of both COX-2 and IKK2 led to PC development in any mice during the observation period of 84 weeks.

Chronic inflammation leads to multiple subtypes of pancreatic cancer in the absence of TP53.

Deletion of TP53 in the pancreas had no obvious effects on pancreatic histology, nor did any TP53−/−/Cre mice developed pancreatic tumors (Figure 1D). However, when COX-2/IKK2 were expressed in mice lacking TP53, all mice developed abdominal swelling, a palpable mass, became moribund, or showed continuous weight loss, leading to death or humanitarian sacrifice. All of the mouse models with CI and TP53 deletion had significantly shorter survival times compared with those only lacking TP53. None of the mice with CI-lacking TP53 survived longer than 65 weeks (Figure 2A). However, we did not observe statistically significant differences among the TP53+/−/COX-2/Cre, TP53−/−/IKK/Cre and TP53−/−/COX-2/IKK/Cre mice.

The mice with CI and TP53 deletion developed large pancreatic tumors up to 3 cm (Supplementary Figure 3A). Examination of these tumors revealed mixed carcinomas of different histologic subtypes, including acinar cell carcinoma (ACC), ductal adenocarcinoma (PDAC), poorly differentiated tumors with sarcomatoid features (SC), as well as neuroendocrine carcinoma (NEC) (Figures 2B and C and Table 1). Interestingly, PDAC, while sometimes present, was not the main component of the mixed carcinomas (30% mice, 6/20) and was always observed mixed with ACC, SC and/or NEC in these mice. For definitive identification of each histologic subtypes, we performed immunohistochemical staining. PDAC was diagnosed as area of tumor showing the typical histological features of ductal adenocarcinoma and positive staining for CK-19 (Figure 2C), a marker of ductal differentiation. ACC was identified as a region with acinar or solid growth pattern showing a positive immunoreactivity for amylase and the absence of cytokeratin 19 staining (Figure 2C). NEC was identified using neuroendocrine markers chromogranin A and synaptophysin. In some tumors, the neuroendocrine carcinoma compartment represented more than 25% of neoplastic cells, which fits the diagnostic criteria for mixed carcinomas of pancreas in humans (Figure 2C).  

Variability in the immune cell infiltration was also observed within tumors (Supplementary Figures 3B and C). Among the variety of cells infiltrating the tumor, we detected an increase in the number of cells positive for Stem cell antigen-1 (Sca-1) (Supplementary Figure 3C). Sca-1 is widely used to detect hematopoietic stem cells and is a candidate marker in the search for tissue-resident and cancer stem cells. Sca-1 is upregulated in many tumors such as retinoblastoma, mammary gland and prostate cancer. Fibroblastic tumors and mammary adenocarcinoma cells expressing high Sca-1 levels are more malignant than tumors with low Sca-1 expression. In addition, we detected the presence of single cells Sca-1 positive in COX-2/Cre and IKK/CreBAC mice (Supplementary Figure 3D). We also assessed the proliferation rate in tumors, which was significantly higher compared with controls, with variability observed between tumor types (Supplementary Figures 4A–D). We also observed DNA damage by positive immunohistochemistry for γH2AX (Supplementary Figures 4E and F). It has been previously reported, that TP53 deletion contributes to metastasis of PC. In this study, we observed metastases to the liver in 30% of tumors. Surprisingly, most of the metastatic carcinomas showed positive strong immunoreactivity for amylase, and weak or negative staining of CK-19, which were consistent with ACC (Figure 2D).
Cancers induced by chronic inflammation in the absence of TP53 showed heterogeneity of cancer-related genes and pathways but oncogenic mutations of K-ras were not detected.

To further characterize the tumors in our mouse models, we next analyzed for the presence or absence of the common genetic alterations known in PC. Point mutations (G12D, G12V) in K-ras are present in the majority of PDAC. In the current study, direct DNA sequencing did not detect K-ras mutations in microdissected histologically defined PDAC areas. It is known to be very difficult to accurately detect the scarce copies of single-base mutated CP is inefficient at inducing PC.

AK Swidnicka-Siergiejko et al

Oncogene (2017) 3149 – 3158
Figure 2. Lack of TP53 and overexpressing COX-2 and/or IKK2 significantly reduced survival and led to the development of mixed pancreatic carcinomas. (A) Mice overexpressing COX-2 and/or IKK2 with TP53 deletion had significantly shorter survival compared with the mice with TP53 deletion alone and controls (TP53+/+). Note: long median survival (Mantel–Cox test) of all groups. (B) Representative H&E images showing histological heterogeneity of tumors; a,b. PDAC: Less cellular, abundant fibrous stroma; (c–f). ACC: highly cellular with scant fibrous stroma and frequent necrosis; (d–f). ACC histological patterns: trabecular (c); acinar (d), solid (e and f); acinar cell cystadenoma (g); sarcomatoid carcinoma (h); chronic inflammatory changes associated with tumor (i) (scale bar: 200 μm, magnification: 10×, 20×). (C) Immunohistochemistry for CK-19, amylase, synaptophysin and chromogranin A confirmed the mixed histology of tumors. (D) Loss of TP53 function in combination with COX-2/IKK overexpression leads to metastatic pancreatic carcinoma. (a, b) Representative H&E of liver metastases. (c) Positive immunohistochemistry for amylase indicate acinar cell carcinoma origin of metastases. (d) Non-specific immunohistochemistry for CK-19 (scale bar: 200 μm, magnification: 10×).
genes in neoplastic tissues among thousands of copies of wild-type DNA. Therefore, we further examined the samples using an alternative approach to analyze gDNA using an locked nucleic acid (LNA) probe to suppress the amplification of the WT allele, which was previously described as allowing sensitive detection of mutant K-ras.11 Consistent with our direct DNA sequencing results, we did not reveal the presence of K-ras mutations using this approach (Figure 3A). In addition, immunohistochemistry using an antibody specific for mutant K-ras did not provide positive staining in these tumors, though it readily identified mutant K-ras expressing cells in control LSL-KrasG12D mice (Figure 3B; Supplementary Figure 5). Despite the lack of detection of mutant K-Ras, the expression of PTEN, which can act as a marker of Ras activation was observed in scattered cells in the areas of PDAC (Figure 3C), as well as occasionally in the expanded ducts in COX-2 expressing animals and acinar cells in IKK expressing mice (Supplementary Figure 6) but was not observed in control mice or non-PDAC tumors.

The tumor suppressor p16 is lost in around 50% of PDAC. However, in genetic mouse models it has been observed that tumors generated by the expression of oncogetic K-ras and deletion of TP53 typically retain p16.12 In agreement with these previous observations, in the present study we found persistent expression of p16 in the majority of the tumors, including within the limited PDAC component. However, loss of p16 expression was observed in some areas of poorly differentiated carcinoma with sarcomatoid features (Figure 4; Supplementary Figure 7), which may indicate more extensive genetic alterations in this cancer subtype.

There is growing evidence that the Hippo signaling pathway may have an important role in PC.13 We noted that ectopic expression of COX-2 led to the upregulation of the major Hippo pathway molecule, Yes-associated Protein (YAP). YAP had a predominant nuclear localization (indicating activation of Hippo pathway) in ductal cells of COX-2/Cre mice at the age of 20 weeks and an increase in nuclear expression mainly within ADM and PanIN lesions at later stages (Supplementary Figure 8A). We determined the YAP expression in the mixed carcinomas developed in this model. The PDAC component showed a predominant nuclear expression of YAP, similar to what is observed in oncogenic K-ras models (LSL-KrasG12D/Cre mice) (Supplementary Figures 8A and B). In contrast, non-PDAC areas of tumors showed predominant cytoplasmic YAP localization and sarcomatoid tumors showed complete loss of YAP expression. In addition, we detected nuclear YAP expression in stromal cells associated with tumors (Figure 5; Supplementary Figure 8A). Our findings confirmed the important role of Hippo pathway in pancreatic tumorigenesis and indicate that different YAP expression patterns occur in different pancreatic tumor types.

Levels of activated c-Myc and Akt were also evaluated. c-Myc protein has an essential role in DNA damage-induced apoptosis through the control of TP53 protein.14 Interestingly, c-Myc induced transformation of acinar cells in transgenic mouse was previously shown to produce both acinar and mixed acinar/ductal neoplasms.15 More recently, serine 62 phosphorylated Myc (pS62Myc), a key residue that is phosphorylated in response to mitogen stimulation and Ras-raf-MEK-ERK signaling, has been shown to play a role in the induction of proliferation of many cells and to be essential for regenerative proliferation in response to DNA damage.16 We found increased nuclear expression pS62Myc only in the PDAC component of the mixed carcinomas and in stromal cells (Figure 5). Increased expression was also detected within ADM and PanIN lesions in COX-2/Cre mice (Supplementary Figure 9A). PI3K/Akt signaling is one of the most commonly deregulated signaling pathways in cancer, including PDAC.17 We detected increased pAkt expression within ADM and PanIN lesions in mice overexpressing COX-2 while only focal pAkt expression was found within tumors (Supplementary Figure 9B).

**DISCUSSION**

In this study, chronic inflammation of the pancreas induced by expression of either COX-2 or IKK2 caused major pathological alterations, but did not induce PC in animals with WT TP53 within 84 weeks (1.6 years). This indicates that chronic inflammation alone is an inefficient driver of PC. In contrast, in the absence of TP53, mixed carcinomas consisting of multiple pancreatic cancer subtypes including PDAC, ACC, SC and NEC consistently developed and were fatal within 65 weeks. Surprisingly, PDAC was not observed.

| Tumor ID | Genotype | PDAC | ACC | SC | Other changes | Liver metastases |
|---------|-----------|------|-----|----|---------------|------------------|
| 1       | TP53−/−/COX-2/Cre | +    | +   | +  | CP, ADM, focal PanIN1s |                  |
| 2       | TP53−/−/COX-2/Cre | +    | +   | +  | Extensive necrosis |                  |
| 3       | TP53−/−/COX-2/Cre | +    | +   | +  | Cystic papillary neoplasm |                  |
| 4       | TP53−/−/COX-2/Cre | +    | +   | +  | Acinar cell cystadenoma |                  |
| 5       | TP53−/−/COX-2/Cre | +    | +   | +  | Lymphoma |                  |
| 6       | TP53−/−/COX-2/Cre | +    | +   | +  | Acinar cell cystadenocarcinoma |                  |
| 7       | TP53−/−/COX-2/Cre | +    | +   | +  | CP, ADM |                  |
| 8       | TP53−/−/COX-2/Cre | +    | +   | +  | Poorly differentiated carcinoma |                  |
| 9       | TP53−/−/COX-2/Cre | +    | +   | +  | Poorly differentiated carcinoma, extensive necrosis | Extensive necrosis |
| 10      | TP53−/−/COX-2/Cre | +    | +   | +  |                  |                  |
| 11      | TP53−/−/COX-2/Cre | +    | +   | +  |                  |                  |
| 12      | TP53−/−/COX-2/Cre | +    | +   | +  |                  |                  |
| 13      | TP53−/−/IKK/Cre | +    | +   | +  |                  |                  |
| 14      | TP53−/−/IKK/Cre | +    | +   | +  |                  |                  |
| 15      | TP53−/−/IKK/Cre | +    | +   | +  |                  |                  |
| 16      | TP53−/−/COX-2/IKK/Cre | + | + | + |                  |                  |
| 17      | TP53−/−/COX-2/IKK/Cre | + | + | + |                  |                  |
| 18      | TP53−/−/COX-2/IKK/Cre | + | + | + |                  |                  |
| 19      | TP53−/−/COX-2/IKK/Cre | + | + | + |                  |                  |
| 20      | TP53−/−/COX-2/IKK/Cre | + | + | + |                  |                  |

Abbreviations: ACC, acinar cell carcinoma; ADM, acinar to ductal metaplasia; CP, chronic pancreatitis; PanIN, pancreatic intraepithelial neoplasia; PDAC, pancreatic ductal adenocarcinoma; SC, sarcomatoid carcinoma. + Represents presence of specific carcinoma subtypes. Note: the wide histological spectrum of tumors in both within genotype and within the same animal.
The predominant component in these tumors and no K-ras mutations were observed. Rather, the histological heterogeneity of the tumors was accompanied by heterogeneous alterations in cancer-related pathways including YAP, pERK, c-Myc and Akt. Therefore, CI, even in the absence of TP53, is ineffective at inducing PDAC, the most common type of human PC. These observations may help explain the rare occurrence of pancreatic cancer in patients with CP and other inflammatory conditions.

In the current study, CI was achieved by transgenic expression of COX-2 or IKK2 in adult pancreatic acinar cells. IKK2 leads to the continuous phosphorylation and degradation of inhibitory proteins controlling NF-kB activation. NF-kB activity is high in CP and PDAC where it regulates the expression of genes involved in inflammation and cell survival. COX-2 is also upregulated in inflammation and is high in patients with CP and PDAC. COX-2 activation is associated with the generation of inflammatory molecules including prostaglandins, prostacyclin and thromboxane A2. Previous genetic mouse models with ectopic expression of COX-2 driven either from the CK5 or elastase promoter reported development of pancreatic fibrosis and a variety of premalignant alterations but no metastatic tumors. Interestingly, expression of COX-2 from the CK5 promoter, which targeted duct cells, caused severe histological alterations and itself was lethal within ~30 weeks. However, it is unclear whether the deaths in that mouse model were accounted for by expression within the pancreas or at other sites. In another study, when inflammatory cytokine IL1b was expressed in mice bearing a copy of mutant TP53R172H/+ there was an increase in ADM, but again no tumors were observed. In the current study, expression of COX-2 or IKK2 in adult acinar cells did not result in tumors within 84 weeks. However, the presence of PanIN lesions in a small minority of the COX-2 expressing mice suggests that with more time cancer might develop and would likely be PDAC.

In the current study, chronic inflammation led to DNA damage in pancreatic acinar cells. In the presence of TP53, this DNA damage caused the loss of acinar cells. The most likely explanation for the observations made in this study is that, in the absence of TP53 mediated apoptosis or senescence, the genetic instability caused by CI eventually led to carcinogenesis. The surviving genetically unstable cells developed a variety of cancer subtypes, indicating no favored pathway to transformation (Figure 6). The development of cancers in the absence of TP53 required a long latency of at least ~9 months. This suggests that even with high levels of genetic instability, the probability of developing alterations required for carcinogenesis is low. We were not able to detect the most common K-ras mutations, which are the most frequent genetic alterations found in PDAC.

PDAC often involves oncogenic mutations of K-ras, with the reported frequency of K-ras mutations in studies of patient samples of PDAC varying greatly from 92% to only 47.2%. The
discrepancies in mutation frequencies could be attributable to differences in the detection methods, specimen types, or the racial characteristics of the patients. In the current study, we were unable to detect the most common mutation of K-ras (G12) even in microdissected areas of PDAC. Single nucleotide mutations are difficult to detect in a background of wild-type genes. Thus, it remains possible that mutations of K-ras existed in some areas of PDAC. We also did not assess other K-ras mutations that are rare in human PDAC samples. Nonetheless, these observations indicate that oncogenic mutation of K-ras was clearly not the predominant pathway of carcinogenesis in these studies. Furthermore, these data indicate that K-ras is neither favored nor necessary for the development of the rarer forms of PC such as ACC or endocrine carcinoma. Interestingly, it was previously observed that PDAC occurring in mouse models with genetic instability caused by BRACA2 deletion plus interference with TP53 were reported to develop invasive PDAC of variable histological features with relatively long latency and to have a very low frequencies of secondarily acquired K-ras gene mutations. Thus, genetic instability per se does not favor mutation of K-ras but rather leads to a variety of genetic alterations and results in heterogeneous tumors.

In the current study, in the absence of TP53 a high percentage of rare tumors were observed, such as ACC, which accounts for about 5 and 15% of PC in adults and children, respectively. ACC is not associated with K-ras mutations. Recently, TP53 genetic alterations were found in ~50% of ACC and were correlated with worse survival. In the current study, sarcomatoid and neuroendocrine tumors were also observed. The preponderance of these rarer forms of PC in these models suggests that loss of TP53 is normally a rare event. Potentially this is explained by the need for two genetic events to lose TP53 function, as a single wild-type allele is sufficient for TP53 activity. The probability of random DNA instability generating two genetic events to block TP53 function is lower than the probability of developing a single mutation in the K-ras gene. This may explain the relative abundance of PDAC compared with the other forms of PC, because when K-ras is mutated as a first hit, the cancer that develops is always PDAC.

In contrast to the relative inefficiency of chronic inflammation to initiate PC, it has been well established that inflammation can accelerate the development of cancer in cells with preexisting oncogene expression. For PC, inflammation greatly accelerates the development of cancer in adult cells bearing activating mutations of K-ras. This effect of inflammation in cells expressing endogenous levels of oncogenic K-ras has been partially explained by the observation the mutant K-ras has very low activity until stimulated by external factors such as inflammatory stimuli. However, once Ras activity is elevated sufficiently, it generates inflammation through its ability to activate mechanisms such as COX-2 and NF-kB, which can perpetuate the cycle. Furthermore, the inflammation generated by high Ras activity is a form of CI and induces genetic instability, increasing the probability of losing a tumor suppressor and developing PDAC. Thus, inflammation is clearly a risk factor once K-ras mutations exist.

In conclusion, this study improves our understanding of the role of chronic inflammation and TP53 loss in the development of pancreatic cancers. The data indicate that chronic inflammation in the presence of TP53 is inefficient at inducing carcinogenesis. In contrast, chronic inflammation in the absence of TP53 generates acinar, ductal, neuroendocrine and sarcomatoid tumors, most of which are rare in patients and are independent of K-ras mutations. Taken together with epidemiological data, these observations suggest that oncogenic mutation of K-ras is a rare consequence of chronic inflammation, but when it occurs it can lead to PDAC. Clearly the mechanisms responsible for K-Ras mutations are important and currently unknown. The loss of TP53 function appears to be even less probable, but when it occurs the result can be several different forms of pancreatic cancer which are K-ras independent.

**MATERIALS AND METHODS**

Genetically engineered transgenic mice

A full-length elastase (Ela) gene promoter was used to drive the expression of tamoxifen-regulated CreERT specifically in adult pancreatic acinar cells in mice (Ela-CreERT) as described previously. COX-2-floxed mice were obtained from Harvey R. Herschman, UCLA, Los Angeles, California, USA. For targeted expression of COX-2 in pancreatic acinar cells, COX-2 floxed mice were bred with Ela-CreERT mice to generate COX-2/Ela-CreERT mice (referred as COX-2/Cre; Supplementary Figure 1). Transgenic mice expressing conditionally active IKK2 were developed as described previously. Briefly, a fragment containing loxP-GFP-stop-loxP followed by active IKK2 (produced by conversion of 2 conserved serines in the
loop of IKK2 with glutamates; a kind gift from Dr. Michael Karin at the University of California, San Diego, USA) was cloned into a pCAGGS vector (provided by Dr Miyazaki, Kamamoto University Medical School, Japan), which contains a cytomegalovirus and a chicken-actin promoter that generates high levels of expression. All transgenic mice were developed by pronuclear injection. For targeted expression of IKK2 in pancreas, IKK2 mice were bred with Ela-CreERT mice to generate IKK2/Ela-CreERT mice (referred as IKK/Cre). Transgenic expression of GFP was visualized under a UV lamp. The TP53-floxed conditional deletion mice were obtained from the Mouse Models for Human Cancer Consortium Repository (Rockville, MD, USA). For targeted pancreas-specific TP53 deletion, mice were bred with Ela-CreERT mice to generate TP53−/−/Cre and with COX-2/Cre and IKK/Cre mice to generate: TP53−/−/COX-2/Cre, TP53−/−/IKK/Cre, and TP53−/−/COX-2/IKK/Cre mice. Tamoxifen treatment was used to induce transgene expression. All experiments were conducted in compliance with the regulations and ethical guidelines for experimental animal studies of the Institutional Animal Care and Use Committee at the University of Texas M.D. Anderson Cancer Center.

Histology
Pancreatic tissues were fixed with 10% formaldehyde in phosphate-buffered saline (PBS), embedded in paraffin, sectioned and stained with hematoxylin and eosin (H&E). Histological analysis was performed by pathologists blinded to experimental procedures. Each mouse pancreas was assessed for the presence of pancreatic changes, including inflammatory cell infiltrate, acinar cell atrophy, fibrosis, ADM, PanIN and histologic subtypes of PC.

Immunohistochemistry
Immunohistochemical staining was performed on pancreatic paraffin sections. Briefly, after deparaffinization, antigen retrieval (DAKO target retrieval solution, DAKO, Carpentaria, CA, USA) was performed in a steamer for 20 min at 98 °C. Endogenous peroxidase activity was blocked with H2O2, followed by washing and blocking, and primary antibodies were applied: α-smooth muscle actin (1:200, Abcam, Cambridge, MA, USA, ab5694), amylase (1:400, ab21156, Abcam), chromogranin A (1:200, Santa Cruz Biotechnology, Dallas, TX, USA, sc1488), cleaved caspase-3 (1:100, Cell Signaling Technology—CST, Danvers, MA, USA, 9664), COX-2 (1: 300; Cayman Chemicals, Ann Arbor, MI, USA, CK-19 (1:100, Abcam, ab15463), CD45 (1:500, BD Pharmingen, San Jose, MO, USA, 553078), F4/80 (1:250, e-Bioscience, San Diego, CA, USA, 14-4801), Ki-67 (1:200, Sigma-Aldrich, St Louis, MO, USA, AB9260), pAkt (1:50, CST, 4060), phospho-ERK (1:200, CST, 4370), CD11b (1:200, Abcam, ab21156), phospho-histone H2AX (1:100, CST, 9718), pS62c-Myc (1:100, Abcam, ab51156), Ras (G12D) mutant specific (1:100, CST, 14429), YAP (1:500, CST, 14074), YAP (1:250, Santa Cruz Biotechnology, sc 15407), synaptophysin (1:500, Abcam, ab32127). After overnight incubation (4 °C), slides were washed with PBS and PBS-containing 0.05% Tween 20, and then incubated with appropriate secondary antibodies ( Vectastatin Elite ABC Kit (Vector Laboratories, Burlingame, CA, USA) for all except pERK for which rabbit on rodent horseradish peroxidase-labeled polymer RMR622H (Biocare Medical, Concord, CA, USA) was used). Positive labeling was detected by exposing the sample to DAB+Substrate system (DAKO). Counterstaining was performed with Gill no. 3 hematoxylin (Sigma-Aldrich).

To calculate the immune cell infiltration per vision field (40 ×; 10 image per case) were included. The immunohistochemical stainings for Ki-67,
Detection of K-ras mutations by qPCR

The tumor cells from PDAC areas of PC were microdissected from paraffin-embedded tissue sections and placed in tubes and xylene was added and centrifuged. Genomic DNA was extracted from the microdissected tumor cells using standard QiAamp DNA FFPE Tissue Kit (Qiagen, 56404) according to the manufacturer’s recommendations. The qPCR was performed to detect K-ras mutation using the LNA-based probe and conditions previously described. The sequence of primers used: K-ras (F: aggctctgctaaagactgct, R: ttcagctggttcattct, wtLNA: cctacgccac-cagctcc-PH; TIB Molbiol, LLC, Adelphia, NJ, USA). For PCR, 20ng of genomic DNA, 0.5 µM of each primers and 0.25 µM of LNA, and SensiMIX Sybr No-Rox Kit (Bioline, Taunton, MA, USA) and water were added to the final volume of 20 µl per reaction. PCR was performed on LightCycler480 (Roche, Indianapolis, IN, USA). gDNA samples that contain K-ras mutations (extracted from tumors of mice carrying K-ras G12D and G12V mutations) and gDNA of wild-type mice (without K-ras mutation) were used as a positive and negative controls, respectively.

Sequencing of PCR products

We performed direct DNA sequencing of all tumor samples. In brief, genomic DNA was isolated from microdissected tumor samples of different PC subtypes, then, a primer pair of forward sequence: gataaagtttgtg tgcgtgagcac and reverse sequence: agatacagaggactatatc attac was used to attempt to amplify K-ras fragments. The PCR products were purified using Qiagen PCR purification kit, and TA ligated into pCR4-TOPO vector (SKU K4595-01, Thermofisher Scientific, Waltham, MA, USA) and then transfected into Escherichia coli. For each samples, we sequenced >20 clones using M13F primer.

Western blot analysis

Pancreas tissues were homogenized in lysis buffer and immunoblot analysis was performed for primary antibodies: pIKKα/β (1:1000, CST, 2697P), COX-2 (1: 2000, CST, 12282S) and GAPDH (1:10 000; Sigma-Aldrich). Briefly, proteins were separated using SDS–PAGE (polyacrylamide gel) cells, transferred to nitrocellulose membranes, and blocked with 5% non-fat milk in PBS-containing 0.05% Tween 20 for 1 h. After overnight incubation (4 °C) with primary antibodies, appropriate secondary antibody was used, and the visualization of protein bands was performed with Odyssey Infrared Imaging System (LI-COR Biosciences, Lincoln, NA, USA).

Statistical analysis

Statistical analysis was performed using the Prism 5 software program (GraphPad Software, San Diego, CA, USA). The percentage of survival was analyzed using the Mantel–Cox method. The median survival in days was presented. The students t-test (two-tailed, two sample equal variance) was used to compare variables between groups. The mean and s.d. values are presented. The P-value < 0.05 was considered significant.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ACKNOWLEDGEMENTS

We thank Dr Bogdan Czerwinski, Dr Tadeusz Majewski and Jolanta Bondaruk from Department of Pathology and Todd Moore from Department of Surgery, University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA for technical support. Grant support: NIH-DK05206, AA020822 and The Lockton Endowment (to CDL).

AUTHOR CONTRIBUTIONS

Study concept and design: ASS, ZCM, BJ and CDL. Study supervision: CDL. Acquisition of data: ASS, ZCM, SGG, DD, HH, BJ and CDL. Analysis and interpreting the results: ASS, BJ, BD, NN, JD, WL, NA and CDL. Technical and material support: LY, JD, NA and WL. Histological characterization and analysis of the pancreatic lesions: HW and AM. Drafting of the manuscript, critical revision for important intellectual content: ASS and CDL. Obtainment of funding: CDL. All authors revised and approved the final version of the manuscript.

REFERENCES

1 Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357: 539–545.
2 Ryan DP, Hong TS, Bardessy N. Pancreatic adenocarcinoma. N Engl J Med 2014; 371: 1039–1049.
3 Cho CH, Yu J. From inflammation to cancer. Advances in Diagnosis and Therapy for Gastrointestinal and Hepatological Diseases. World Scientific Publishing Co.: Singapore, 2012.
4 Murata M, Thanan R, Ma N, Kawanishi S. Role of nitrative and oxidative DNA damage in inflammation-related carcinogenesis. J Biomed Biotechnol 2012; 2012: 623019.
5 Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009; 7: 1073–1081.
CP is inefficient at inducing PC
AK Swidnicka-Sergiejko et al

6 Ji B, Song J, Tsou L, Bi Y, Gaiser S, Mortensen R, Logsdon C. Robust acinar cell transgene expression of CreERT via BAC recombinering. Genesis 2008; 46: 390–395.

7 Wood LD, Klimstra DS. Pathology and genetics of pancreatic neoplasms with acinar differentiation. Semin Diagn Pathol 2014; 31: 491–497.

8 La Rosa S, Sessa F, Capella C. Acinar cell carcinoma of the pancreas: overview of clinicopathologic features and insights into the molecular pathology. Front Med 2015; 2: 41.

9 Holmes C, Stanford WL. Concise review: stem cell antigen-1: expression, function, and enigma. Stem Cells 2007; 25: 1339–1347.

10 Morton JP, Klimstra DS, Mongeau ME, Lewis BC. TrTP53 deletion stimulates pancreatic ductal adenocarcinoma and in stellate cells associated with cancer and mutant-specific probes. Mutat Res 2009; 677: 27–32.

11 Hu Y, Le Leu RK, Young GP. Detection of K-ras mutations in azoxymethane-induced aberrant crypt foci in mice using LNA-mediated real-time PCR clamping and mutant-specific probes. Mutat Res 2009; 1087.

12 Bardeesy N, Aguirre AJ, Chu GC, Cheng KH, Lopez LV, Hezel AF et al. Both p16 (Ink4a) and the p19(Arf)-TP53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci USA 2006; 103: 5947–5952.

13 Morvaridi S, Dhall D, Greene MI, Pandol SJ, Wang Q. Role of YAP and TAZ in pancreatic ductal adenocarcinoma and in stellate cells associated with cancer and chronic pancreatitis. Sci Rep 2015; 5: 16759.

14 Phesse TJ, Myant KB, Cole AM, Ridgway RA, Pearson H et al. Endogenous c-Myc is essential for TP53-induced apoptosis in response to DNA damage in vivo. Cell Death Differ 2014; 21: 956–966.

15 Grippo PJ, Sandgren EP. Acinar-to-ductal metaplasia accompanies c-myc-induced exocrine pancreatic cancer progression in transgenic rodents. Int J Cancer 2012; 131: 1242–1248.

16 Myant K, Qiao X, Halonen M, Lewis BC. Overexpression of interleukin-1beta in the murine pancreas results in chronic pancreatitis. Gastroenterology 2008; 135: 1277–1287.

17 Urban T, Ricci S, Grange JD, Lacave R, Boudghene F, Brettmayer F et al. Detection of K-ras mutation by PCR/RFLP analysis and diagnosis of pancreatic adenocarcinomas. J Natl Cancer Inst 1993; 85: 2008–2012.

18 Kwon MJ, Jeon JY, Park HR, Nam ES, Cho SJ, Shin HS et al. Low frequency of KRAS mutation in pancreatic ductal adenocarcinomas in Korean patients and its prognostic value. Pancreas 2015; 44: 484–492.

19 Cox AD, Frese KE, Kimmelman AC, Luo J, Der CJ. Drugging the undruggable Ras: mission possible? Nat Rev Drug Disc 2014; 13: 828–851.

20 Rowley M, Ohashi A, Mondal G, Mills L, Yang L, Zhang L et al. Inactivation of Brc2a promotes TrTP53-associated but inhibits KrasG12D-dependent pancreatic cancer development in mice. Gastroenterology 2011; 140: 1303–1313.

21 Jiao Y, Yonescu R, Offerhaus GJ, Klimstra DS, Matra A, Eshleman JR et al. Whole-exome sequencing of pancreatic neoplasms with acinar differentiation. J Pathol 2014; 232: 428–435.

22 Bardeesy N, Bernasconi B, Frattini M, Poli D, Molinari F, Furlan D et al. TP53 alterations in pancreatic acinar cell carcinoma: new insights into the molecular pathology of this rare cancer. Virchows Arch 2015; 468: 286–296.

23 Guerra C, Schuhmacher AJ, Calamero M, Grippo PJ, Verduguer L, Perez-Gallego L et al. Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell 2007; 11: 291–302.

24 Huang H, Daniluk J, Liu Y, Chu J, Li Z, Ji B et al. Oncogenic K-Ras requires activation for enhanced activity. Oncogene 2014; 33: 532–535.

25 Marrache F, Tu SP, Bhagat G, Pendyala S, Osterweich CH, Gordon S et al. Overexpression of interleukin-1beta in the murine pancreas results in chronic pancreatitis. Gastroenterology 2008; 135: 1277–1287.

26 Urban T, Ricci S, Grange JD, Lacave R, Boudghene F, Brettmayer F et al. Detection of K-ras mutation by PCR/RFLP analysis and diagnosis of pancreatic adenocarcinomas. J Natl Cancer Inst 1993; 85: 2008–2012.

27 Kwon MJ, Jeon JY, Park HR, Nam ES, Cho SJ, Shin HS et al. Low frequency of KRAS mutation in pancreatic ductal adenocarcinomas in Korean patients and its prognostic value. Pancreas 2015; 44: 484–492.

28 Cox AD, Frese KE, Kimmelman AC, Luo J, Der CJ. Drugging the undruggable Ras: mission possible? Nat Rev Drug Disc 2014; 13: 828–851.

29 Feldmann G, Karkari C, dal Molin M, Düringer S, Vollmann P, Bartsch DK et al. Inactivation of Brc2a cooperates with TrTP53(R172H) to induce invasive pancreatic ductal adenocarcinomas in mice: a mouse model of familial pancreatic cancer. Cancer Biol Ther 2011; 11: 959–968.

30 Rowley M, Ohashi A, Mondal G, Mills L, Yang L, Zhang L et al. Inactivation of Brc2a promotes TrTP53-associated but inhibits KrasG12D-dependent pancreatic cancer development in mice. Gastroenterology 2011; 140: 1303–1313.

31 Jiao Y, Yonescu R, Offerhaus GJ, Klimstra DS, Matra A, Eshleman JR et al. Whole-exome sequencing of pancreatic neoplasms with acinar differentiation. J Pathol 2014; 232: 428–435.

32 Bardeesy N, Bernasconi B, Frattini M, Poli D, Molinari F, Furlan D et al. TP53 alterations in pancreatic acinar cell carcinoma: new insights into the molecular pathology of this rare cancer. Virchows Arch 2015; 468: 286–296.

33 Guerra C, Schuhmacher AJ, Calamero M, Grippo PJ, Verduguer L, Perez-Gallego L et al. Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell 2007; 11: 291–302.

34 Huang H, Daniluk J, Liu Y, Chu J, Li Z, Ji B et al. Oncogenic K-Ras requires activation for enhanced activity. Oncogene 2014; 33: 532–535.

35 Daniluk J, Liu Y, Deng D, Chu J, Huang H, Gaiser S et al. An NF-kB pathway-mediated positive feedback loop amplifies Ras activity to pathological levels in mice. J Clin Invest 2012; 122: 951–968.

36 Philip B, Roland CL, Daniluk J, Liu Y, Chatterjee D, Gomez SB et al. A high-fat diet activates oncogenic Kras and COX2 to induce development of pancreatic ductal adenocarcinoma in mice. Gastroenterology 2013; 145: 1449–1458.

37 Jonkers J, Meuwissen R, van der GH, Peterse H, van der Valk M, Berns A. Synergistic tumor suppressor activity of BRC2A and TP53 in a conditional mouse model for breast cancer. Nat Genet 2001; 29: 418–425.

© The Author(s) 2017

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/